IS7884A - Díasepínóindól afleiður sem kínasa hindrar - Google Patents

Díasepínóindól afleiður sem kínasa hindrar

Info

Publication number: IS7884A
Authority: IS; Iceland
Prior art keywords: inhibit kinase; diazepinoindole; derivatives; diazepinoindole derivatives; kinase
Prior art date: 2003-01-09

Application number

IS7884A

Other languages

English (en)

Inventor

Ninkovic Sacha

John Bennett Michael

Yuanjin Rui Eugene

Wang Fen

Pritchett Benedict Suzanne

Teng Min

Wang Yong

Zhu Jinjiang

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-09

Filing date

2005-06-09

Publication date

2005-06-09

2005-06-09 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2005-06-09 Publication of IS7884A publication Critical patent/IS7884A/is

Links

108091000080 Phosphotransferase Proteins 0.000 title 1
102000020233 phosphotransferase Human genes 0.000 title 1
BSYFXFLGOGQHFU-UHFFFAOYSA-N pyrrolo[2,3-g][1,2]benzodiazepine Chemical class N1=NC=CC=C2C3=NC=CC3=CC=C21 BSYFXFLGOGQHFU-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IS7884A 2003-01-09 2005-06-09 Díasepínóindól afleiður sem kínasa hindrar IS7884A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US43939603P	2003-01-09	2003-01-09
PCT/IB2004/000026 WO2004063198A1 (en)	2003-01-09	2004-01-05	Diazepinoindole derivatives as kinase inhibitors

Publications (1)

Publication Number	Publication Date
IS7884A true IS7884A (is)	2005-06-09

Family

ID=32713475

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7884A IS7884A (is)	2003-01-09	2005-06-09	Díasepínóindól afleiður sem kínasa hindrar

Country Status (34)

Country	Link
US (3)	US6967198B2 (is)
EP (2)	EP1585749B1 (is)
JP (1)	JP3990718B2 (is)
KR (1)	KR100697746B1 (is)
CN (1)	CN1759118B (is)
AP (1)	AP2048A (is)
AT (1)	ATE404564T1 (is)
AU (1)	AU2004203977B2 (is)
BR (1)	BRPI0406701A (is)
CA (1)	CA2512683C (is)
CR (1)	CR7899A (is)
CY (1)	CY1108408T1 (is)
DE (1)	DE602004015724D1 (is)
DK (1)	DK1585749T3 (is)
EA (1)	EA009337B1 (is)
EC (1)	ECSP055911A (is)
ES (1)	ES2309484T3 (is)
GE (1)	GEP20084367B (is)
HR (1)	HRP20050624A2 (is)
IL (1)	IL169082A (is)
IS (1)	IS7884A (is)
MA (1)	MA27703A1 (is)
MX (1)	MXPA05007352A (is)
NO (1)	NO20053775L (is)
NZ (1)	NZ540638A (is)
OA (1)	OA13017A (is)
PL (1)	PL378372A1 (is)
PT (1)	PT1585749E (is)
RS (1)	RS20050522A (is)
SI (1)	SI1585749T1 (is)
TN (1)	TNSN05176A1 (is)
UA (1)	UA80733C2 (is)
WO (1)	WO2004063198A1 (is)
ZA (1)	ZA200504674B (is)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003214879B2 (en) *	2002-01-22	2008-02-07	The Regents Of The University Of California	Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
PL378372A1 (pl) *	2003-01-09	2006-04-03	Pfizer Inc.	Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii
KR20070107034A (ko) *	2005-02-18	2007-11-06	아스트라제네카 아베	Ｃｈｋ1 억제제에 대한 반응성의 결정 방법
HRP20100678T1 (hr)	2005-03-29	2011-02-28	Icos Corporation	Derivati heteroariluree korisni kao inhibitori chk1
GB0510390D0 (en) *	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
US8003625B2 (en)	2005-06-29	2011-08-23	Threshold Pharmaceuticals, Inc.	Phosphoramidate alkylator prodrugs
CA2619048A1 (en) *	2005-08-15	2007-02-22	The Regents Of The University Of California	Vegf-activated fas ligands
JP4935675B2 (ja)	2005-08-25	2012-05-23	宇部興産株式会社	光学活性（Ｓ又はＲ）−α−アミノ酸及び光学活性（Ｒ又はＳ）−α−アミノ酸エステルの製造方法
WO2007025303A2 (en) *	2005-08-26	2007-03-01	The Regents Of The University Of California	Non-steroidal antiandrogens
AU2007232279B2 (en) *	2006-04-04	2010-05-06	Pfizer Products Inc.	Combination therapy of (2R)-2-amino-2-cyclohexyl-N-(2-(1-methyl-1H-pyrazol-4-yl)-6- oxo-5,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
EP2004655A1 (en) *	2006-04-04	2008-12-24	Pfizer Products Incorporated	Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4 l)-1-oxo-2,6-dihydro-1h-ý1,2¨diazepinoý4,5,6-cd¨indol-8-yl)acetamide
CA2669982A1 (en) *	2006-11-17	2008-05-29	Schering Corporation	Combination therapy for proliferative disorders
US8158656B2 (en) *	2008-05-16	2012-04-17	Shenzhen Chipscreen Biosciences Ltd.	2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
JP5576370B2 (ja) *	2008-08-06	2014-08-20	ファイザー・インク	Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
EP2346881A1 (en) *	2008-10-10	2011-07-27	Priaxon AG	Novel compounds which modulate kinase activity
US8314108B2 (en)	2008-12-17	2012-11-20	Eli Lilly And Company	5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en)	2009-05-13	2014-03-04	Novian Health, Inc.	Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en)	2009-05-22	2012-07-03	Shenzhen Chipscreen Biosciences Ltd.	Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh)	2009-06-04	2013-03-13	深圳微芯生物科技有限责任公司	作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
AU2012253759B2 (en)	2011-05-06	2016-01-21	Zafgen Inc.	Tricyclic sulfonamide compounds and methods of making and using same
US9254299B2 (en)	2011-12-22	2016-02-09	Threshold Pharmaceuticals, Inc.	Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer
SG11201403538TA (en)	2011-12-31	2014-09-26	Beigene Ltd	Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
NO2797921T3 (is) *	2011-12-31	2018-02-03
CN102746211B (zh) *	2012-06-27	2015-05-27	上海泰坦化学有限公司	一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) *	2013-05-22	2018-08-21	開曼群島商百濟神州生物科技有限公司	作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
CA2928568A1 (en)	2013-07-26	2015-01-29	Update Pharma Inc.	Combinatorial methods to improve the therapeutic benefit of bisantrene
US10071109B2 (en)	2013-11-06	2018-09-11	Molecular Templates, Inc.	Predictive biomarker for hypoxia-activated prodrug therapy
PL3157566T3 (pl)	2014-06-17	2019-10-31	Vertex Pharma	Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
IL257442B2 (en)	2015-08-25	2023-03-01	Beigene Ltd	Process for preparing parp inhibitor, crystalline forms and their uses
KR102678021B1 (ko)	2015-09-30	2024-06-26	버텍스 파마슈티칼스 인코포레이티드	Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
WO2018059437A1 (en)	2016-09-27	2018-04-05	Beigene, Ltd.	Treatment cancers using combination comprising parp inhibitors
JP6541635B2 (ja) *	2016-10-28	2019-07-10	ベイジーンリミテッド	Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
WO2018157794A1 (en)	2017-02-28	2018-09-07	Beigene, Ltd.	Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof
US11661581B2 (en) *	2017-05-25	2023-05-30	University Of Massachusetts	Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
SG11202002032SA (en) *	2017-09-22	2020-04-29	Jubilant Epipad LLC	Heterocyclic compounds as pad inhibitors
EP3461480A1 (en)	2017-09-27	2019-04-03	Onxeo	Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
JP2022523028A (ja) *	2019-01-25	2022-04-21	ヌメディー，インコーポレイテッド	特発性肺線維症を処置するための方法
WO2021018298A1 (zh) *	2019-08-01	2021-02-04	南京明德新药研发有限公司	作为parp抑制剂吲哚并七元酰肟化合物
CN114746413B (zh)	2019-11-29	2024-02-23	南京明德新药研发有限公司	二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
WO2022011458A1 (en) *	2020-07-13	2022-01-20	Ontario Institute For Cancer Research (Oicr)	Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
CN115698019B (zh) *	2020-07-31	2024-12-06	正大天晴药业集团股份有限公司	用作parp抑制剂的吲哚并七元酰肟类似物的结晶及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9722320D0 (en)	1997-10-22	1997-12-17	Janssen Pharmaceutica Nv	Human cell cycle checkpoint proteins
US6383744B1 (en)	1998-07-10	2002-05-07	Incyte Genomics, Inc.	Human checkpoint kinase
JP2002526450A (ja)	1998-09-18	2002-08-20	スミスクライン・ビーチャム・コーポレイション	Ｃｈｋ１キナーゼ阻害物質
EE05006B1 (et) *	1999-01-11	2008-04-15	Agouron Pharmaceuticals, Inc.	Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid
WO2001016306A2 (en)	1999-08-27	2001-03-08	Chiron Corporation	Chimeric antisense oligonucleotides and cell transfecting formulations thereof
ECSP003637A (es)	1999-08-31	2002-03-25	Agouron Pharma	Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en)	1999-11-01	2003-12-30	Agouron Pharmaceuticals, Inc.	Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
EP1218494B1 (en)	1999-09-22	2005-04-06	Canbas Co., Ltd.	Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
US6211164B1 (en)	2000-03-10	2001-04-03	Abbott Laboratories	Antisense oligonucleotides of the human chk1 gene and uses thereof
MXPA03004832A (es)	2000-12-01	2004-05-04	Guilford Pharm Inc	Compuestos y sus usos.
UA76977C2 (en)	2001-03-02	2006-10-16	Icos Corp	Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
PL378372A1 (pl) *	2003-01-09	2006-04-03	Pfizer Inc.	Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii

2004
- 2004-01-05 PL PL378372A patent/PL378372A1/pl not_active Application Discontinuation
- 2004-01-05 JP JP2006500278A patent/JP3990718B2/ja not_active Expired - Fee Related
- 2004-01-05 WO PCT/IB2004/000026 patent/WO2004063198A1/en not_active Ceased
- 2004-01-05 PT PT04700145T patent/PT1585749E/pt unknown
- 2004-01-05 NZ NZ540638A patent/NZ540638A/en unknown
- 2004-01-05 DE DE602004015724T patent/DE602004015724D1/de not_active Expired - Lifetime
- 2004-01-05 AT AT04700145T patent/ATE404564T1/de not_active IP Right Cessation
- 2004-01-05 KR KR1020057012806A patent/KR100697746B1/ko not_active Expired - Fee Related
- 2004-01-05 HR HR20050624A patent/HRP20050624A2/hr not_active Application Discontinuation
- 2004-01-05 SI SI200430830T patent/SI1585749T1/sl unknown
- 2004-01-05 EP EP04700145A patent/EP1585749B1/en not_active Expired - Lifetime
- 2004-01-05 AP AP2005003353A patent/AP2048A/xx active
- 2004-01-05 CA CA2512683A patent/CA2512683C/en not_active Expired - Fee Related
- 2004-01-05 ES ES04700145T patent/ES2309484T3/es not_active Expired - Lifetime
- 2004-01-05 GE GEAP20048886A patent/GEP20084367B/en unknown
- 2004-01-05 RS YUP-2005/0522A patent/RS20050522A/sr unknown
- 2004-01-05 DK DK04700145T patent/DK1585749T3/da active
- 2004-01-05 CN CN2004800063838A patent/CN1759118B/zh not_active Expired - Fee Related
- 2004-01-05 AU AU2004203977A patent/AU2004203977B2/en not_active Ceased
- 2004-01-05 EP EP08155745A patent/EP1947102A1/en not_active Withdrawn
- 2004-01-05 MX MXPA05007352A patent/MXPA05007352A/es active IP Right Grant
- 2004-01-05 EA EA200500893A patent/EA009337B1/ru not_active IP Right Cessation
- 2004-01-05 BR BR0406701-0A patent/BRPI0406701A/pt not_active IP Right Cessation
- 2004-01-05 OA OA1200500197A patent/OA13017A/en unknown
- 2004-01-09 US US10/754,171 patent/US6967198B2/en not_active Expired - Fee Related
- 2004-05-01 UA UAA200506730A patent/UA80733C2/uk unknown
2005
- 2005-06-08 ZA ZA200504674A patent/ZA200504674B/en unknown
- 2005-06-08 IL IL169082A patent/IL169082A/en not_active IP Right Cessation
- 2005-06-09 IS IS7884A patent/IS7884A/is unknown
- 2005-07-08 EC EC2005005911A patent/ECSP055911A/es unknown
- 2005-07-08 TN TNP2005000176A patent/TNSN05176A1/fr unknown
- 2005-07-08 MA MA28375A patent/MA27703A1/fr unknown
- 2005-07-08 CR CR7899A patent/CR7899A/es unknown
- 2005-07-22 US US11/187,089 patent/US7132533B2/en not_active Expired - Fee Related
- 2005-08-08 NO NO20053775A patent/NO20053775L/no unknown
2006
- 2006-06-23 US US11/426,132 patent/US7462713B2/en not_active Expired - Fee Related
2008
- 2008-10-13 CY CY20081101127T patent/CY1108408T1/el unknown

Also Published As

Publication number	Publication date
CA2512683A1 (en)	2004-07-29
DE602004015724D1 (de)	2008-09-25
JP2006516274A (ja)	2006-06-29
IL169082A (en)	2011-02-28
ECSP055911A (es)	2005-11-22
KR100697746B1 (ko)	2007-03-22
NO20053775L (no)	2005-09-16
AU2004203977A1 (en)	2004-07-29
MA27703A1 (fr)	2006-01-02
EP1947102A1 (en)	2008-07-23
EA009337B1 (ru)	2007-12-28
PT1585749E (pt)	2008-10-23
NO20053775D0 (no)	2005-08-08
ATE404564T1 (de)	2008-08-15
HK1086257A1 (en)	2006-09-15
US20060004052A1 (en)	2006-01-05
AU2004203977B2 (en)	2010-06-17
WO2004063198A1 (en)	2004-07-29
US6967198B2 (en)	2005-11-22
UA80733C2 (en)	2007-10-25
SI1585749T1 (sl)	2008-10-31
US7462713B2 (en)	2008-12-09
CA2512683C (en)	2010-03-16
CN1759118A (zh)	2006-04-12
CN1759118B (zh)	2010-12-08
ES2309484T3 (es)	2008-12-16
NZ540638A (en)	2007-12-21
RS20050522A (sr)	2007-12-31
EP1585749A1 (en)	2005-10-19
TNSN05176A1 (fr)	2007-06-11
ZA200504674B (en)	2006-07-26
PL378372A1 (pl)	2006-04-03
BRPI0406701A (pt)	2005-12-20
HRP20050624A2 (en)	2006-02-28
CY1108408T1 (el)	2014-02-12
OA13017A (en)	2006-11-10
KR20050092397A (ko)	2005-09-21
EP1585749B1 (en)	2008-08-13
MXPA05007352A (es)	2006-02-17
AP2048A (en)	2009-09-24
EA200500893A1 (ru)	2006-02-24
US20070135415A1 (en)	2007-06-14
JP3990718B2 (ja)	2007-10-17
AP2005003353A0 (en)	2005-09-30
US20050075499A1 (en)	2005-04-07
DK1585749T3 (da)	2008-09-22
US7132533B2 (en)	2006-11-07
GEP20084367B (en)	2008-05-13
CR7899A (es)	2005-08-05

Publication	Publication Date	Title
AP2048A (en)	2009-09-24	Diazepinoindole derivatives as kinase inhibitors
IS7328A (is)	2004-06-21	Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum
IS8345A (is)	2006-03-09	6-útskipt anilínópúrín sem RTK-tálmar
IL173381A0 (en)	2006-06-11	2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
ATE505471T1 (de)	2011-04-15	Azaindol-kinaseinhibitoren
DK1704145T3 (da)	2012-09-24	Selektive kinaseinhibitorer
IS7505A (is)	2004-10-14	Pýrróló-tríazín anilín efnasambönd gagnleg sem kínasatálmar
IS8238A (is)	2006-01-18	Pýrrólótvíhýdróísókínólín sem PDE10 tálmar
IS7717A (is)	2005-02-28	Pýrídasínónafleiður sem PDF4-hemlar
IL172132A0 (en)	2006-04-10	Thienopyridone derivatives as kinase inhibitors
ATE340782T1 (de)	2006-10-15	Piperidinbenzolsulfonamidderivate
IS2581B (is)	2010-02-15	Kínólín afleiður sem fosfódíesterasa hindrar
IS8077A (is)	2005-10-14	Risahringa qínazólínafleiður sem miðlar gegn fjölgun
ATE352550T1 (de)	2007-02-15	Chinazolinderivate
ATE420066T1 (de)	2009-01-15	Amidoacetonitrilderivate
DK1606277T3 (da)	2008-08-18	Imidazol-4-yl-ethynyl-pyridinderivater
IL172375A0 (en)	2009-02-11	Chinazoline derivatives as aurora kinase inhibitors
ATE433032T1 (de)	2009-06-15	Verriegelungsanordnung
DK1682129T3 (da)	2007-06-11	N-thiazol-2-ylbenzamidderivater
DK1713805T3 (da)	2009-08-17	Kinaseinhibitorer
ATE449064T1 (de)	2009-12-15	Amidoacetonitrilderivate
DE502004003715D1 (de)	2007-06-14	Selbstsperrender gurtaufroller
IS8045A (is)	2005-09-26	Púrín-6-ón-afleiður
DE502004001587D1 (de)	2006-11-09	Arretierelement
EP1804796A4 (en)	2009-10-21	AMINO-SUBSTITUTED ARYLOXYBENZYLPIPERIDINE DERIVATIVES